Filing Details

Accession Number:
0001214659-19-000676
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-01-31 19:00:14
Reporting Period:
2019-01-29
Accepted Time:
2019-01-31 19:00:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1370348 A Craig Johnson C/O Mirati Therapeutics Inc.
9393 Towne Centre Drive, Ste 200
San Diego CA 92121
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-01-29 7,000 $15.79 7,000 No 4 M Direct
Common Stock Acquisiton 2019-01-29 10,000 $3.65 17,000 No 4 M Direct
Common Stock Disposition 2019-01-29 8,475 $61.11 8,525 No 4 S Direct
Common Stock Disposition 2019-01-29 8,525 $61.80 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (Right to Buy) Disposition 2019-01-29 7,000 $0.00 7,000 $15.79
Common Stock Non-Qualified Stock Option (Right to Buy) Disposition 2019-01-29 10,000 $0.00 10,000 $3.65
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-11-07 No 4 M Direct
0 2027-05-16 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018.
  2. This transaction was executed in multiple trades at prices ranging from $60.43 to $61.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $61.44 to $62.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. 1/4th of the shares subject to the Option shall vest and become exercisable on September 4, 2014, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
  5. The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.